Bayer Pulls Aliqopa Combo Filings In EU, US & Other Markets – But May Resubmit

 
• By Neena Brizmohun

The company plans to conduct additional analyses of data from ongoing trials that are testing its PI3K inhibitor in combination with rituximab for treating types of indolent B-cell non-Hodgkin’s lymphoma.

Doctors and medical researchers on conference meeting, discussing possible solutions for resolving a world health crisis.
More data will be analyzed from studies of Aliqopa used in combination with rituximab • Source: Alamy

More from Product Reviews

More from Pink Sheet